drugset / Trial / NCT06190067
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |